SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement.
1. A SARS vaccine was produced based on recombinant native full-length Spike-protein trimers (triSpike) and efficient establishment of a vaccination procedure in rodents. 2. Antibody-mediated enhancement of SARS-CoV infection with anti-SARS-CoV Spike immune-serum was observed in vitro. 3. Antibody-mediated infection of SARS-CoV triggers entry into human haematopoietic cells via an FcγR-dependent and ACE2-, pH-, cysteine-protease-independent pathways. 4. The antibody-mediated enhancement phenomenon is not a mandatory component of the humoral immune response elicited by SARS vaccines, as pure neutralising antibody only could be obtained. 5. Occurrence of immune-mediated enhancement of SARS-CoV infection raises safety concerns regarding the use of SARS-CoV vaccine in humans and enables new ways to investigate SARS pathogenesis (tropism and immune response deregulation).
HKU-Pasteur Research Centre, 8 Sassoon Road, Hong Kong SAR, China. firstname.lastname@example.org
SourceHong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine 18 Suppl 2: 2012 Feb pg 31-6
Cell Line, Tumor
Mice, Inbred BALB C
Severe Acute Respiratory Syndrome
Viral Envelope Proteins
Pub Type(s)Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't